Augustine Therapeutics Revenue and Competitors

Leuven, BE

Location

$93M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Augustine Therapeutics's estimated annual revenue is currently $3.6M per year.(i)
  • Augustine Therapeutics's estimated revenue per employee is $155,000
  • Augustine Therapeutics's total funding is $93M.

Employee Data

  • Augustine Therapeutics has 23 Employees.(i)
  • Augustine Therapeutics grew their employee count by 53% last year.

Augustine Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Medical OfficerReveal Email/Phone
3
Head Non-Clinical and Early DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.6M17-6%$82.2MN/A
#2
$3.6M2353%$93.4MN/A
#3
$1.1M70%N/AN/A
#4
$5.4M3513%$38.9MN/A
#5
$5.1M3327%$16.4MN/A
#6
$17.4M11233%N/AN/A
#7
$5.1M2729%$66.1MN/A
Add Company

What Is Augustine Therapeutics?

Augustine Therapeutics focuses on the discovery and development of innovative medicines to benefit patients suffering from Charcot-Marie-Tooth disease (CMT) and other peripheral neuropathies, neurodegenerative and cardiometabolic disorders. The company is rooted in the ground-breaking research at VIB and KU Leuven and supported by Asabys Partners, Eli Lilly and Company, V-Bio Ventures, PMV, AdBio Partners, VIB, Gemma Frisius Fund and CMT Research Foundation.\n \n——— *Disclaimer* ——— \nWe wish to caution jobseekers that Augustine Therapeutics, only recruits for the positions that are posted on the company’s webpage and via the channels mentioned there. It will also not charge fees of any kind from candidates during the recruitment process. Any person or organization dealing with unauthorized parties is doing so at their own risk.

keywords:N/A

$93M

Total Funding

23

Number of Employees

$3.6M

Revenue (est)

53%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.9M2315%$3M
#2
$2.7M23-12%N/A
#3
$3.7M32-38%N/A
#4
$4.4M3448%N/A
#5
$8.6M3657%$40M